BioCardia Secures Nasdaq Extension, Believes Delisting Risk Mitigated by $4.9M ATM Raise
BCDA is trading near its 52-week low of $0.777 (2.9% above the low) on light trading volume (0.3× avg).
Summary
BioCardia received a Nasdaq extension until October 7, 2026, to regain compliance with listing rules, following a $4.9 million ATM offering that the company believes has resolved its stockholders' equity deficiency.
Key Events · Corporate Governance and Compliance · BCDA
-
Nasdaq Delisting Extension Granted
Nasdaq granted an extension until October 7, 2026, for BioCardia to regain compliance with the minimum $2.5 million stockholders' equity requirement, following a prior delisting notice on April 15, 2026.
-
$4.9 Million Capital Raise
The company sold 4,004,330 shares through an At-The-Market (ATM) offering between April 1 and June 5, 2026, at an average price of $1.27 per share, generating net proceeds of $4.9 million.
-
Belief of Compliance
BioCardia believes these ATM sales have enabled it to regain compliance with Nasdaq's stockholders' equity rule, temporarily mitigating the immediate delisting threat.
Analysis · BCDA · Life Sciences
BioCardia, facing imminent delisting due to low stockholders' equity and a critical cash runway, has received an extension from Nasdaq until October 7, 2026. The company believes it has regained compliance by raising $4.9 million through an At-The-Market (ATM) offering, which involved selling shares at an average price of $1.27. While this capital raise is highly dilutive, it provides a crucial temporary reprieve from delisting and extends the company's financial runway, allowing more time to address its underlying financial challenges.
At the time of this filing, BCDA was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.8M. The 52-week trading range was $0.78 to $2.45. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.